DermTech. has been granted a patent for a non-invasive method to diagnose non-melanoma skin cancers, specifically basal cell carcinoma and squamous cell carcinoma. The method involves isolating nucleic acids from skin samples and detecting gene expression levels using specific probes to identify the presence of cancer. GlobalData’s report on DermTech gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on DermTech, Predictive cancer diagnosis models was a key innovation area identified from patents. DermTech's grant share as of June 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Non-invasive detection of non-melanoma skin cancer
The granted patent US11976332B2 outlines a method for the non-invasive identification of non-melanoma skin cancers (NMSC), specifically basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The method involves isolating nucleic acids from a skin sample collected via an adhesive patch from a subject suspected of having NMSC. The isolated nucleic acids are then contacted with a set of probes that target specific genes of interest, including COL5A2, IL24, AADACL2, PRKACA, and SPP1. The binding between these genes and the probes is measured to determine the presence of NMSC, leading to surgical intervention for removal or partial removal of the cancerous tissue.
Additionally, the patent describes the potential for repeated sampling and analysis of multiple skin samples to enhance diagnostic accuracy. It includes methods for differentiating between cancerous and non-cancerous skin samples, utilizing pair-wise interactions of genes to generate an area under the curve (AUC) value for diagnostic purposes. The method claims a sensitivity of at least 90% and specificity of at least 70% for differentiating between primary cutaneous BCC and SCC and benign lesions. Furthermore, the patent encompasses the analysis of gene expression levels and mutational changes, providing insights into disease state, treatment success likelihood, and disease progression. Overall, this patent presents a comprehensive approach to the non-invasive detection and treatment of non-melanoma skin cancers.
To know more about GlobalData’s detailed insights on DermTech, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
